Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Drug symbols : Bmy save search
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
Published: 2024-02-14 (Crawled : 15:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.23%
H: 0.44%
C: 0.14%
drug review food tumors treatment application advanced
Implantable Drug Delivery Devices Global Market to Exhibit Growth at a Considerable CAGR of ~6% by 2028, Assesses DelveInsight
Published: 2024-01-23 (Crawled : 23:00) - prnewswire.com
TRUMF | $16.928 -17.59% 1.9K
|
Health Technology
|
| O: -4.99%
H: 0.0%
C: -0.06%
TRUMY | $16.507 0.79% 34K
|
Manufacturing
|
| O: -1.36%
H: 0.0%
C: -0.82%
WST | $372.04 -1.4% 0.0% 440K
|
Health Technology
|
| O: 0.67%
H: 0.46%
C: -1.49%
TFX | $206.56 -0.4% 0.0% 420K
|
Health Technology
|
| O: 0.18%
H: 0.52%
C: -2.57%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.61%
H: 1.52%
C: 0.03%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.16%
H: 0.84%
C: 0.08%
BSX | $67.33 -0.13% -0.31% 7M
|
Health Technology
|
| O: -0.18%
H: 0.5%
C: -0.98%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.44%
H: 0.0%
C: 0.0%
PODD | $166.255 0.93% 0.92% 840K
|
Health Technology
|
| O: 0.07%
H: 1.08%
C: -1.59%
drug global growth market
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab)
Published: 2023-12-05 (Crawled : 16:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.36%
H: 1.2%
C: 0.86%
drug opdivo review food application
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
Published: 2023-11-06 (Crawled : 13:00) - globenewswire.com
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.61%
H: 0.77%
C: -0.66%
ADXS | $0.57 12.48% 9.5K
|
Health Technology
|
| O: 6.74%
H: 0.0%
C: -10.53%
al102 drug tumors pharmaceuticals designation
Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance
Published: 2023-09-18 (Crawled : 06:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.02%
H: 0.18%
C: -0.78%
drug antibody cancer agreement
Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance
Published: 2023-09-17 (Crawled : 00:00) - prnewswire.com
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.02%
H: 0.18%
C: -0.78%
drug antibody cancer agreement
Nanotechnology Drug Delivery Market to Reach $209.5 Billion, Globally, by 2032 at 9.1% CAGR: Allied Market Research
Published: 2023-07-19 (Crawled : 09:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 0.47%
H: 1.47%
C: 1.47%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.97%
H: 0.0%
C: 0.0%
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: 1.23%
H: 4.13%
C: 4.01%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.61%
H: 0.6%
C: -0.84%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.19%
H: 1.19%
C: -0.1%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.5%
H: 0.75%
C: -0.32%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.18%
H: 0.67%
C: -0.4%
drug reach research market
U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label
Published: 2023-06-16 (Crawled : 10:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.32%
H: 2.1%
C: 1.97%
camzyos drug label food positive study
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Published: 2023-05-30 (Crawled : 12:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.71%
H: 1.14%
C: 0.54%
lung drug review food cancer cell treatment application
Ulcerative Colitis Drug Global Market Report 2022: Increasing Prevalence of Ulcerative Colitis and Inflammatory Bowel Diseases Bolsters Sector
Published: 2023-04-07 (Crawled : 11:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
| Email alert
Add to watchlist
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
| Email alert
Add to watchlist
drug report global market
CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs
Published: 2023-03-20 (Crawled : 12:20) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.3%
H: 0.97%
C: 0.76%
drug collaboration therapeutics
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) ….
Published: 2023-02-28 (Crawled : 16:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.27%
H: 0.2%
C: -1.2%
drug application opdivo license food nivolumab
U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for CAMZYOS® (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduction Therapy
Published: 2022-10-21 (Crawled : 12:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.0%
H: 3.08%
C: 2.64%
camzyos drug application food therapy
Advanced Parenteral Drug Delivery Devices Market to hit US$ 4.99 Billion by 2030 | Exclusive Report by Growth Plus Reports
Published: 2022-10-06 (Crawled : 14:20) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -2.53%
H: 0.0%
C: 0.0%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -1.91%
H: 1.22%
C: -0.8%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.69%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -1.42%
H: 0.38%
C: -0.3%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -1.25%
H: 0.53%
C: -0.1%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.92%
H: 0.06%
C: -0.78%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.5%
H: 0.34%
C: -0.4%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -2.45%
H: 0.54%
C: -0.78%
drug report plus growth market
U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis
Published: 2022-09-10 (Crawled : 08:20) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
| Email alert
Add to watchlist
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
| Email alert
Add to watchlist
treatment drug psoriasis food plague
Disease-Modifying Antirheumatic Drug (DMARD) Market to Surpass US$ 27,167.8 Million by 2030 - Coherent Market Insights
Published: 2022-09-06 (Crawled : 19:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -3.02%
H: 0.0%
C: 0.0%
UCBJY | $63.676 -4.38% 7.2K
|
Manufacturing
|
| O: 0.73%
H: 2.28%
C: 1.72%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.65%
H: 0.93%
C: 0.71%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.03%
H: 1.18%
C: 0.13%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.03%
H: 1.08%
C: 0.84%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.49%
H: 0.0%
C: 0.0%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.44%
H: 2.03%
C: 1.76%
CPIX | $1.65 6.02% 790
|
Health Technology
|
| O: -4.52%
H: 7.12%
C: 5.69%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.24%
H: 1.04%
C: 0.82%
drug market
A $41.8 Billion Global Opportunity for Small Molecule Drug Discovery by 2026 - New Research from StrategyR
Published: 2022-07-04 (Crawled : 11:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
| Email alert
Add to watchlist
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
| Email alert
Add to watchlist
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
| Email alert
Add to watchlist
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
| Email alert
Add to watchlist
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
| Email alert
Add to watchlist
drug research
Antiviral Drugs Market is expected to grow at a steady pace by 2027 | CAGR: 3.4% | UnivDatos Market Insights
Published: 2022-05-30 (Crawled : 15:20) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
| Email alert
Add to watchlist
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
| Email alert
Add to watchlist
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
| Email alert
Add to watchlist
antiviral expected market drug
Antiviral Drugs Market Size To Reach USD 50.02 BN In 2030 Due to Development Of New, Improved, And More Advanced Formulations, Such As Repurposed Drugs And Drug Combination Therapies, Says Reports and Data
Published: 2022-04-13 (Crawled : 15:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.76%
H: 0.35%
C: 0.35%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -0.83%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.12%
H: 0.44%
C: 0.17%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.08%
H: 0.0%
C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.24%
H: 0.45%
C: 0.39%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.24%
H: 0.53%
C: 0.18%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -1.38%
H: 0.0%
C: -3.67%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.02%
H: 0.8%
C: 0.71%
drug antiviral repurposed market
Immune Checkpoint Inhibitors Market Report 2022-2030: Increase in Number of Pipeline Drugs & Growth Opportunities in Emerging Markets
Published: 2022-03-28 (Crawled : 16:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 3.37%
H: 0.0%
C: -0.19%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.58%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.8%
H: 0.39%
C: 0.11%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.91%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.0%
H: 0.71%
C: 0.38%
report growth market drug
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.